To what extent do the PANSS and CGI-S overlap?

Journal of Clinical Psychopharmacology

Volumn 26, Issue 3, 2006, Pages 303-307

  Rabinowitz, Jonathan ^a   Mehnert, Angelika ^b   Eerdekens, Marielle ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; HOSTILITY; HUMAN; INTERMETHOD COMPARISON; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; REGRESSION ANALYSIS; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA;

EID: 33744462861     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000218407.10362.6e     Document Type: Article

References (16)

1. Guy W. Clinical Global Impression (CGI). In: Rush AJ, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:100-102.
2. Dahlke F, Lohaus A, Gutzmann H. Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research. Psychopharmacol Bull. 1992;28(4):425-432.
3. Khan A, Khan SR, Shankles EB, et al. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions Rating Scale in antidepressant clinical trials. Int Clin Psychopharmacol. 2002;17(6):281-285.
4. Khan A, Brodhead AE, Kolts RL. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions Rating Scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol. 2004;19(3):157-160.
5. Bandelow B, Brunner E, Beinroth D, et al. Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. Eur Arch Psychiatry Clin Neurosci. 1999;249(1):21-27.
6. Zaider TI, Heimberg RG, Fresco DM, et al. Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med. 2003;33(4):611-622.
7. Goldman M, DeQuardo JR, Tandon R, et al. Symptom correlates of global measures of severity in schizophrenia. Compr Psychiatry. 1999;40(6):458-461.
8. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238.
9. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum; 1976.
10. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546.
11. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166:712-726.
12. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825-835.
13. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162:947-953.
14. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111-117.
15. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125-1132.
16. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting risperidone: a 12-month evaluation of the first long-acting injectable atypical antipsychotic. J Clin Psychiatry. 2003;64:1250-1257.